Dogwood Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), before Tax
Dogwood Therapeutics, Inc. (DWTX) reported Foreign Currency Transaction Gain (Loss), before Tax of -$30.57 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-14
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$30.57K, a 774.51% decline year-over-year.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$5.86K.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $8.34K.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$17.51K.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$27.92K.
- Dogwood Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$30.79K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$30.57K 10-Q · filed 2026-08-14 | -$36.43K 10-Q · filed 2026-08-14 | -$28.09K derived: sum of 3 quarters · filed 2026-08-14 | -$45.60K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$5.86K 10-Q · filed 2026-05-15 | $2.48K derived: sum of 2 quarters · filed 2026-05-15 | -$15.03K derived: sum of 3 quarters · filed 2026-05-15 | -$10.50K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $8.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$9.17K derived: sum of 2 quarters · filed 2026-03-18 | -$4.64K derived: sum of 3 quarters · filed 2026-08-14 | -$27.92K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$17.51K 10-Q · filed 2025-11-07 | -$12.98K derived: sum of 2 quarters · filed 2026-08-14 | -$36.25K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $4.53K 10-Q · filed 2026-08-14 | -$18.74K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | -$23.27K 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$30.79K 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |